Brand Name(s):Tarceva
Indication:Non-small-cell lung cancer (First line treatment)
Rationale:1,2,3,8
Considered:Sep-12
Review Date:Dec-20
Comments:
NICE TA374
Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
Full document can be found at:http://www.nice.org.uk/guidance/ta374/resources/erlotinib-and-gefitinib-for-treating-nonsmallcell-lung-cancer-that-has-progressed-after-prior-chemotherapy-82602789240517
Dec 2015
…………………………
1.1 Erlotinib is recommended as an option for the first-line treatment of people with locally advanced or metastatic non-small-cell lung cancer (NSCLC) if:
they test positive for the epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation and the manufacturer provides erlotinib at the discounted price agreed under the patient access scheme (as revised in 2012).
NICE Guidance TA258 June 2012